clinical trial · NCT07213609
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline·phase2·recruiting·n = 47
Neoplasms, ColorectalNeoplasmsGSK5460025
brief summary
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.
started
Oct 20, 2025
primary completion
Sep 28, 2028
completion
Oct 27, 2028
last updated
Mar 23, 2026
official title
A Phase 1/2 Open-label, Multicenter Study of Oral GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol